III期非小细胞肺癌根治性放疗中免疫系统受照剂量对肿瘤控制与生存的影响
本研究回顾性分析单中心117例2004-2017年接受根治性放疗的III期非小细胞肺癌患者,计算免疫细胞估计受照剂量(EDRIC)。中位随访16个月,中位EDRIC为6.1 Gy,较高EDRIC与≥3级淋巴细胞减少风险增加相关,且在多因素分析中独立关联总生存、局部无进展生存和无病生存。EDRIC>7.3 Gy组中位OS为14.3个月,<5.1 Gy组为28.2个月。
要点
- EDRIC>7.3 Gy组中位OS为14.3个月,<5.1 Gy组为28.2个月。
核心结论
- 较高免疫系统受照剂量与III期非小细胞肺癌根治性放疗后肿瘤进展和死亡相关。
研究设计与样本
- 单中心回顾性队列研究,纳入2004-2017年117例接受根治性分次放疗的III期非小细胞肺癌患者,中位剂量60 Gy,60%接受调强放疗,92%接受同步铂类化疗。
主要发现
- 全队列5年OS为11.2%,中位生存17.3个月,中位随访16个月,77%患者随访至死亡。
- 全队列中位EDRIC为6.1 Gy(范围2.5-10.0 Gy)。
- EDRIC>7.3 Gy(第四四分位)和<5.1 Gy(第一四分位)患者的中位OS分别为14.3个月和28.2个月。
临床怎么用
- 在III期非小细胞肺癌根治性放疗中,可考虑评估EDRIC以识别免疫系统受照剂量较高的患者。
- 优化放疗计划以保护免疫系统可能是改善该人群预后的未来方向。
局限性
- 本研究为单中心回顾性分析,样本量117例,中位随访16个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The significance of radiation dose to the host immune system during the treatment of stage III non-small cell lung cancer (NSCLC) is unknown, but higher doses were associated with worse tumor control and overall survival (OS) in a secondary analysis of RTOG 0617. In this study, we sought to assess the impact of the estimated dose of radiation to immune cells (EDRIC) on cancer-specific outcomes in an independent cohort of patients treated at our institution. METHODS AND MATERIALS: We retrospectively identified 117 patients with stage III NSCLC treated with definitive fractionated radiation from 2004 to 2017 at a single academic center (median dose of 60 Gy; 60% underwent intensity modulated radiation therapy and 92% received concurrent platinum-based chemotherapy). EDRIC was calculated as a function of the number of radiation fractions and mean doses to the lung, heart, and remaining body based on a model developed by Jin et al. RESULTS: Median follow-up was 16 months with 77% of patients followed until death. In the entire population, 5-year OS was 11.2% with a median survival of 17.3 months. Median EDRIC for the entire cohort was 6.1 Gy (range, 2.5-10.0 Gy). A higher EDRIC was correlated with greater risk of grade ≥3 lymphopenia (P = .004). On multivariate analysis including total prescription radiation dose, planning target volume, and chemotherapy utilization, EDRIC was independently associated with OS (hazard ratio [HR] 1.17, P = .03), local progression-free survival (HR 1.17, P = .02), and disease-free survival (HR 1.15, P = .04). The median OS for patients with an EDRIC above 7.3 Gy (fourth quartile) and below 5.1 Gy (first quartile) was 14.3 and 28.2 months, respectively. CONCLUSIONS: Higher doses of radiation to the immune system were associated with tumor progression and death after the definitive treatment of stage III NSCLC. Tailoring radiation therapy to spare the immune system may be an important future direction to improve outcomes in this population.
引用
- Ladbury CJ, Rusthoven CG, Camidge DR, et al. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019. PMID: 31175902. doi:10.1016/j.ijrobp.2019.05.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。